Full Press Release Details
Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients.
BIIB
Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients
Key Takeaway: Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis